Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-ANG3 in Diabetic Kidney Disease
NCT07271186Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Oct 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of ALN-ANG3 in diabetic kidney disease (DKD), sponsored by Regeneron Pharmaceuticals. Started Jan 2026; status: recruiting.
02
Drugs
ALN-ANG3
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT07271186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07271186.